Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Ranbaxy Laboratories Stories

2009-09-08 08:59:00

NEW YORK, Sept. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. FoodService Disposables http://www.reportlinker.com/p0131234/FoodService-Disposables.html This report analyzes the US market for FoodService Disposables in Millions of US$ by the following Product Types: Cups and Lids, Containers, Dinnerware, Napkins, and Others. This report also analyzes the US Market for Foodservice Disposables by End-Use Segments: Restaurants,...

2009-09-02 06:00:00

PRINCETON, N.J., Sept. 2 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), Gurgaon, India, announced an agreement with Validus Pharmaceuticals LLC (Validus) to market and distribute an authorized generic version of Rocaltrol(R) (calcitriol) in both softgel capsules and an oral liquid formulation. Overall market sales for calcitriol softgel capsules and oral liquid were $70 million (IMS - MAT: June 2009). Rocaltrol(R)...

2009-08-24 09:39:00

PRINCETON, N.J., Aug. 24 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Glycopyrrolate Tablets USP, 1 mg and 2 mg. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed...

2009-08-11 17:08:00

KENILWORTH, N.J., Aug. 11 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced an agreement with Orchid Chemicals & Pharmaceuticals Ltd. and Orgenus Pharma, Inc. ("Orchid"), related to the generic manufacturing of certain formulations of CLARINEX(R) (desloratadine). The agreement marks the end of all pending litigations filed and consolidated since 2006 in the U.S. District Court for the District of New Jersey against several generic drug manufacturing...

2009-08-11 08:06:00

PRINCETON, N.J., Aug. 11 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received final approval from the U.S. Food and Drug Administration to manufacture and market Sumatriptan Succinate Tablets, 25 mg (base), and 50 mg (base). The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as...

9e2ed01b1f60bac0647592f18bba85c5
2009-05-03 08:05:00

Due to manufacturing problems, India's largest drugmaker announced Saturday the recall of an antibiotic currently being sold in the United States.  The company has witnessed a huge setback as a result of the recall, the Associated Free Press accounted. The antibiotic capsules called nitrofurantoin, which is commonly used to treat urinary tract infections, was voluntarily recalled by the Japanese-operated company.  The company did not disclose any specific information about the...

2009-05-01 18:00:00

PRINCETON, N.J., May 1 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI) announced today that it is conducting a voluntary recall of all lots of Nitrofurantoin (Monohydrate/Macrocrystals) Capsules, USP 100 mg currently on the market in the U.S. Although certain lots of the product were determined to not be in conformity with the approved laboratory specifications, Ranbaxy decided to recall all the lots, as a matter of abundant caution, given its commitment to the health and safety of...

2009-04-02 09:20:02

The U.S. Food and Drug Administration has approved the first generic versions of Topamax tablets (topiramate) to prevent seizures. The federal agency said prescribing information or labeling for generic topiramate will differ from the innovator drug, Topamax, because some uses of Topamax are protected by patents and exclusivity. The labeling for both Topamax and generic topiramate contain a safety warning about metabolic acidosis, a condition associated with excessive acid in the blood that...

2009-03-05 10:09:00

PRINCETON, N.J., March 5 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Quinapril Hydrochloride & Hydrochlorothiazide (Quinapril + HCTZ) Tablets, 10mg/12.5mg, 20mg/12.5mg and 20mg/25mg. The Application for the drug was submitted by Ranbaxy, from its Ohm Laboratories manufacturing facility located in...

2009-02-25 14:23:00

GURGAON, India, Feb. 25 /PRNewswire/ -- Ranbaxy has just received a letter and information indicating that all pending and approved ANDAs from Ranbaxy's Paonta Sahib facility have been added to a list maintained under a policy entitled "Application Integrity Policy" or "AIP". Ranbaxy will analyze the letter and other information fully and respond appropriately in a timely manner. The FDA has said it has no evidence the drugs on the market are substandard and also that they comply with...